SecBot SecBot

Community Health Center Drug Pricing Protection Act

H.R. 7391 Rep. Jack Bergman (R-MI-1) In committee
Bill text PDF
  1. Introduced Feb 5
  2. Committee Feb 5
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Feb 5, 2026Next: House vote
265d ago Feb 5, 2026: Referred to the House Committee on Energy and Commerce.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
5companies, 11 filings
Subscribe to see spend
Member trades
14trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

5 companies
Companies by sector
Biotech & Pharma 5
Search all 5 companies, their asks and price moves Subscribe

Summary

This bill amends the Public Health Service Act to require that Federally-qualified health centers (FQHCs) pay no more than the 340B ceiling price for covered outpatient drugs at the time of purchase, rather than through later rebates or reimbursements.

Sec. 2, Ensuring upfront 340B discounted pricing for Federally-qualified health centers: The bill adds a new paragraph to the 340B program requiring that the Secretary of Health and Human Services cannot enter into a drug pricing agreement with a manufacturer that would require an FQHC to pay more than the 340B ceiling price at the point of purchase. It clarifies that this does not allow any arrangement where the FQHC pays more upfront and later gets a rebate or other payment to reconcile the difference. The changes take effect on the date the bill is enacted and apply to drugs purchased on or after that date, and existing agreements must comply with these requirements from the enactment date.

Summary of the bill text as introduced in House (Feb 5, 2026), generated by SecBot from the official bill text; the Library of Congress summary is not yet published.

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 27, 2026.